11 — Chronic inflammation (chronic inflammation, "inflammaging")
"Integrative" hallmark added explicitly in the update by López-Otín et al., Cell 2023 (10.1016/j.cell.2022.11.001). It brings together age-related low-grade inflammation, immunosenescence and clonal hematopoiesis.
1. Definition
With age, the body maintains a weak but permanent inflammation, with no apparent infection or injury. Franceschi named it inflammaging (inflammation + aging) (Franceschi 2000, 10.1111/j.1749-6632.2000.tb06651.x). At the same time, the immune system becomes less effective against real threats (immunosenescence).
In plain terms: the body's fire alarm keeps ringing softly all the time. It wears out the tissues, but when a real fire (infection, cancer) breaks out, the firefighters are tired and respond badly.
2. Mechanisms and sources
- Debris and danger signals: the accumulation of damaged molecules ("garbaging") activates innate immune sensors such as the NLRP3 inflammasome. In mice, removing NLRP3 reduces systemic inflammation and age-related functional decline (Youm 2013, 10.1016/j.cmet.2013.09.010; review: Franceschi 2018, 10.1038/s41574-018-0059-4).
- DNA out of place (cGAS-STING): DNA leaking from the nucleus or mitochondria is detected as an intruder by the sensor cGAS, which activates STING. This pathway sustains age-related inflammation and neurodegeneration; blocking it improves function in old mice (Gulen 2023, 10.1038/s41586-023-06373-1).
- Senescent cells (SASP): they secrete inflammatory cytokines (IL-6, IL-1β…), see 08 and 10.
- Clonal hematopoiesis (CHIP): blood stem cells carrying mutations (genes DNMT3A, TET2, ASXL1, JAK2) proliferate. CHIP affects more than 10% of people over 70 and increases the risk of blood cancer and of mortality (Jaiswal 2014, 10.1056/NEJMoa1408617; definition: Steensma 2015, 10.1182/blood-2015-03-631747). It roughly doubles the risk of coronary disease (Jaiswal 2017, 10.1056/NEJMoa1701719). Mechanism: TET2-deficient macrophages produce more IL-1β via NLRP3, which accelerates atherosclerosis in mice (Fuster 2017, 10.1126/science.aag1381). Inherited variants predispose to CHIP (Bick 2020, 10.1038/s41586-020-2819-2).
- Aging immune cells: T lymphocytes with faulty mitochondria are enough to trigger systemic inflammation and premature multi-organ senescence in mice (Desdín-Micó 2020, 10.1126/science.aax0860). Old macrophages, whose metabolism is disrupted by the prostaglandin PGE2, sustain brain inflammation; restoring their metabolism reverses cognitive decline in mice (Minhas 2021, 10.1038/s41586-020-03160-0).
- Leaky gut and microbiota: bacterial products pass into the blood and activate immunity (see 12).
- Visceral fat tissue and obesity: a major source of inflammatory cytokines.
3. Symptoms and clinical manifestations
Chronic inflammation is a risk factor shared by most age-related diseases (Furman 2019, 10.1038/s41591-019-0675-0):
- Cardiovascular disease: atherosclerosis, heart attack, heart failure (Ferrucci 2018, 10.1038/s41569-018-0064-2).
- Type 2 diabetes, chronic kidney disease, fatty liver disease.
- Neurodegeneration and cognitive decline.
- Cancers (notably blood cancers in CHIP carriers).
- Frailty, sarcopenia, loss of autonomy.
- Weaker vaccine response, more severe infections.
Measurement in humans: high-sensitivity CRP, IL-6 and TNF-α are associated with mortality and multimorbidity in older people. An "inflammatory clock" (iAge), built by deep learning on blood cytokines, tracks multimorbidity, immunosenescence and frailty (Sayed 2021, 10.1038/s43587-021-00082-y).
4. Interactions with the other hallmarks
- Genomic instability (01): mutations in blood stem cells create CHIP; misplaced DNA activates cGAS-STING.
- Telomere attrition (02): triggers senescence and therefore the SASP.
- Epigenetic alterations (03): CHIP mutations hit epigenetic regulators (DNMT3A, TET2).
- Loss of proteostasis (04) and disabled macroautophagy (05): uncleared debris acts as danger signals.
- Deregulated nutrient sensing (06): mTOR and excess calories fuel inflammation; caloric restriction and rapalogs reduce it.
- Mitochondrial dysfunction (07): released mitochondrial DNA activates inflammation; T lymphocytes with faulty mitochondria (Desdín-Micó 2020).
- Cellular senescence (08): the SASP is a major driver of inflammaging.
- Stem cell exhaustion (09): CHIP is both a form of HSC exhaustion and a source of inflammation; inflammation in turn favours clonal expansion.
- Altered intercellular communication (10): inflammation is the dominant "message" in old blood.
- Dysbiosis (12): intestinal permeability and pro-inflammatory bacteria.
5. Existing or investigational remedies
| Intervention | Target | Level of evidence | Key result | Source |
|---|---|---|---|---|
| Canakinumab (anti-IL-1β), CANTOS trial | IL-1β | Human phase III trial | −15% cardiovascular events in post-heart-attack patients with high CRP; more fatal infections | Ridker 2017 |
| Low-dose colchicine, COLCOT | Post-heart-attack inflammation | Human phase III trial | Fewer ischemic events after heart attack | Tardif 2019 |
| Low-dose colchicine, LoDoCo2 | Chronic coronary disease | Human phase III trial; approved (FDA 2023) for cardiovascular prevention | Fewer cardiovascular events | Nidorf 2020 |
| NLRP3 inhibition (genetic) | Inflammasome | Preclinical (mice) | Less inflammation and functional decline | Youm 2013 |
| STING inhibition | cGAS-STING pathway | Preclinical (mice) | Less inflammation, better cognitive and physical function | Gulen 2023 |
| Blocking the PGE2 receptor EP2 | Old macrophages | Preclinical (mice) | Cognitive decline reversed | Minhas 2021 |
| Moderate caloric restriction (CALERIE) | Systemic inflammation | Randomised human trial (2 years) | Lower inflammatory markers without impairing immunity | Meydani 2016 |
| mTORC1 inhibitors (rapalogs) | Immunosenescence | Human phase IIa trial | Better vaccine response, fewer infections in older people | Mannick 2018 |
| Senolytics (dasatinib + quercetin) | Senescent cells / SASP | Open-label human pilot trial (pulmonary fibrosis, n=14) | Improved physical function, feasible | Justice 2019 |
| Metformin (TAME project) | Metabolism, inflammation | Proposed human trial (TAME, no results yet) | Rationale for targeting aging itself | Barzilai 2016 |
Key point: CANTOS is the proof in humans that reducing inflammation alone reduces age-related diseases. But the price is a higher risk of infection: the target must be chosen carefully.
6. Open questions
- Which targets? IL-1β, IL-6, NLRP3, STING… Which one reduces inflammaging without weakening defence against infections and cancers?
- Whom to treat? CHIP carriers (notably TET2) might benefit most from anti-IL-1β/IL-6: a hypothesis from secondary analyses, to be tested prospectively.
- Cause or consequence? Is inflammation a driver of aging or mostly a marker? Randomised trials with "aging" endpoints are lacking.
- Measurement: iAge and other inflammatory clocks must be validated as endpoints in trials.
- CHIP: can the expansion of mutated clones be prevented? No validated treatment so far.
7. References
- López-Otín C. et al. (2023) Hallmarks of aging: An expanding universe. Cell. 10.1016/j.cell.2022.11.001
- Franceschi C. et al. (2000) Inflamm-aging: an evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 10.1111/j.1749-6632.2000.tb06651.x
- Franceschi C. et al. (2018) Inflammaging: a new immune–metabolic viewpoint for age-related diseases. Nature Reviews Endocrinology. 10.1038/s41574-018-0059-4
- Ferrucci L., Fabbri E. (2018) Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nature Reviews Cardiology. 10.1038/s41569-018-0064-2
- Furman D. et al. (2019) Chronic inflammation in the etiology of disease across the life span. Nature Medicine. 10.1038/s41591-019-0675-0
- Sayed N. et al. (2021) An inflammatory aging clock (iAge) based on deep learning tracks multimorbidity, immunosenescence, frailty and cardiovascular aging. Nature Aging. 10.1038/s43587-021-00082-y
- Youm Y.-H. et al. (2013) Canonical Nlrp3 inflammasome links systemic low-grade inflammation to functional decline in aging. Cell Metabolism. 10.1016/j.cmet.2013.09.010
- Gulen M.F. et al. (2023) cGAS–STING drives ageing-related inflammation and neurodegeneration. Nature. 10.1038/s41586-023-06373-1
- Desdín-Micó G. et al. (2020) T cells with dysfunctional mitochondria induce multimorbidity and premature senescence. Science. 10.1126/science.aax0860
- Minhas P.S. et al. (2021) Restoring metabolism of myeloid cells reverses cognitive decline in ageing. Nature. 10.1038/s41586-020-03160-0
- Jaiswal S. et al. (2014) Age-related clonal hematopoiesis associated with adverse outcomes. NEJM. 10.1056/NEJMoa1408617
- Steensma D.P. et al. (2015) Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 10.1182/blood-2015-03-631747
- Jaiswal S. et al. (2017) Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. NEJM. 10.1056/NEJMoa1701719
- Fuster J.J. et al. (2017) Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science. 10.1126/science.aag1381
- Bick A.G. et al. (2020) Inherited causes of clonal haematopoiesis in 97,691 whole genomes. Nature. 10.1038/s41586-020-2819-2
- Ridker P.M. et al. (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. NEJM. 10.1056/NEJMoa1707914
- Tardif J.-C. et al. (2019) Efficacy and safety of low-dose colchicine after myocardial infarction. NEJM. 10.1056/NEJMoa1912388
- Nidorf S.M. et al. (2020) Colchicine in patients with chronic coronary disease. NEJM. 10.1056/NEJMoa2021372
- Meydani S.N. et al. (2016) Long-term moderate calorie restriction inhibits inflammation without impairing cell-mediated immunity. Aging. 10.18632/aging.100994
- Mannick J.B. et al. (2018) TORC1 inhibition enhances immune function and reduces infections in the elderly. Sci Transl Med. 10.1126/scitranslmed.aaq1564
- Justice J.N. et al. (2019) Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. EBioMedicine. 10.1016/j.ebiom.2018.12.052
- Barzilai N. et al. (2016) Metformin as a tool to target aging. Cell Metabolism. 10.1016/j.cmet.2016.05.011